+86-28-82633987
Product name: Salvianolic acid B
Synonym name: Danshensuan B; Lithospermic acid B; Extra Cas No: 115939-25-8
Catalogue No.: BP1248
Cas No.: 121521-90-2
Formula: C36H30O16
Mol Weight: 718.62
Botanical Source: Salviae Miltiorrhizae Radix et Rhizoma
Physical Description:
Type of Compound: Phenylpropanoids
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
Chengdu Biopurify Phytochemicals Ltd. is a leading company in the research, development, manufacture and marketing of High Quality Phytochemicals and Extracts(especially Active Ingredients from Traditional Chinese Medicine，TCM), Natural Active Pharmaceutical Ingredients worldwide.
The main services:
A. Supply active ingredients and reference standards of TCM, from mgs to kgs scale
B. Custom extraction and purification, target Herb Active Ingredients
C. Custom synthesis and semi-synthesis for Natural Active Ingredients
D. CR(contract research), CM(contract manufacture) and PD(process development) services from lab scale, pilot scale to commercial scale(GMP is also available)
E. TCM compounds library for drug screen,more than 3000 compounds available, many of them are rare and unique.
HPLC of Salvianolic acid B
NMR of Salvianolic acid B
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
278.0400
2.4687
-.2180
.1268
1.0901
.1640
Low
92.5706
4.5409
Yes
No
No
No
Yes
No
0.0
Yes
Yes
Yes
No
Salvianolic acid B (CAS number: 121521-90-2) is an important water-soluble phenolic compound isolated from Salvia miltiorrhiza, a traditional Chinese medicine, and belongs to the 1-benzofuran class of natural products. As a relatively high and highly active component in Danshen, Danphenolic acid B has attracted significant attention in traditional Chinese medicine due to its diverse pharmacological effects. In recent years, with the development of modern pharmacology and molecular biology technologies, the biological activity and mechanism of action of Danphenic acid B have been extensively studied, demonstrating its potential in antioxidant, anti-inflammatory, cardiovascular and cerebrovascular protection, anti-tumor, neuroprotection, and metabolic regulation, especially in the prevention and treatment of microcirculation diseases.
This paper aims to systematically review the chemical structure and physicochemical properties, plant origin, and extraction methods of Danphenic Acid B, comprehensively evaluate its pharmacological activity and mechanism of action, analyze its clinical development potential in combination with druggability parameters, and look ahead to its application prospects in modern medicine, providing theoretical basis and research directions for natural product pharmacology and new drug development.
Danphenol B has the molecular formula C36H30O16 and a molecular weight of 718.62, classifying it as a polyphenolic compound. Its structural feature is a complex polyphenol system formed by two caffeic acid units connected by ester bonds and benzofuran rings, rich in hydroxyl and phenol carboxyl groups, which impart excellent antioxidant activity. The chemical framework of Danphenol B is stable and possesses strong free radical scavenging ability.
In terms of physicochemical properties, the LogP value of Danphenolic acid B is 2.4687, indicating moderate lipophilus, which facilitates cell membrane penetration without excessive lipid dissolution. Its topological polar surface area (TPSA) is 278.04, and the relatively high polar surface area reflects its good water solubility (solubility about 0.1268 mg/mL), which also aligns with its characteristics as a water-soluble phenolic compound. Danphenic acid B has a relatively low penetration ability to the blood-brain barrier, suggesting that its direct effect in the central nervous system may be limited. In terms of safety, Danphenol B does not inhibit hERG channels, and the Ames-induced mutagenic test results are negative, indicating a solid safety foundation.
Danphenic acid B mainly comes from the Lamiaceae plant Salvia miltiorrhiza Bunge, a traditional Chinese medicinal herb widely distributed in China and East Asia. The root of Danshen is rich in danphenic acid compounds, with Danheoic acid B being the most abundant and biologically active component.
The extraction method usually uses water extraction or alcohol extraction combined with liquid chromatography for separation and purification. Traditional processes mostly use water or ethanol-water mixed solvents for reflux extraction, followed by multi-stage solvent extraction, column chromatography (such as silica gel columns, C18 reversed-phase columns), and high-performance liquid chromatography (HPLC) to obtain high-purity tanphenol acid B. In recent years, the application of ultrasound-assisted extraction, microwave-assisted extraction, and membrane separation technologies has improved extraction efficiency and purity, reduced process costs, and promoted the large-scale production of danphenic acid B.
The pharmacological activities of Danphenic Acid B are rich and diverse, covering antioxidant, anti-inflammatory, antithrombotic, cardiovascular and cerebrovascular protection, neuroprotection, anti-tumor, blood sugar-lowering, and osteogenesis regulation.
Danphenol B contains a rich phenolic hydroxyl structure, which can effectively scavenge free radicals, inhibit lipid peroxidation, and protect cells from oxidative stress damage. In vitro experiments showed that Danphenol B can significantly increase the activity of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx), reduce malondialdehyde (MDA) levels, and lessen oxidative damage.
Danphenol B exerts antithrombotic effects by regulating various blood coagulation factors and platelet activation-related targets (such as PTGS1, F2, F7, F9, F10, ITGA2B, ITGB3, P2RY12, TBXA2R, SERPINC1). It can inhibit platelet aggregation, reduce blood viscosity, improve microcirculation, prevent thrombosis, and has potential cardiovascular and cerebrovascular protective effects.
Danphenic acid B suppresses inflammatory responses by downregulating the nuclear factor κB (NF-κB) signaling pathway and related inflammatory mediators. It has demonstrated effects in reducing tissue inflammation and lowering levels of inflammatory factors (such as TNF-α, IL-1β, IL-6) across various inflammation models.
Danphenic acid B can reduce oxidative stress and inflammatory damage to nerve cells, inhibit apoptosis, and promote nerve regeneration. It demonstrated significant neuroprotective and antidepressant activity in animal models of ischemic brain injury, Parkinson's disease, and depression.
Danphenic acid B intervenes in the tumor microenvironment by inducing tumor cell apoptosis, inhibiting proliferation and migration, and demonstrates multi-target anti-tumor activity. Its mechanism of action involves regulating the cell cycle, activating apoptosis-related proteins, and inhibiting tumor-related signaling pathways.
Danphenic acid B can improve insulin resistance, promote glucose metabolism, lower blood sugar levels, and provide protection against diabetes and its complications.
Danphenol B promotes osteoblast differentiation and inhibits osteoclast activity, aiding in the treatment of osteoporosis and other bone metabolic diseases.
The multiple pharmacological effects of Danphenolic Acid B depend on its regulation of various molecular targets and mainly involve the following aspects:
Danphenic acid B alleviates oxidative stress by directly scavenging reactive oxygen species (ROS), nitrogen radicals (RNS), and activating endogenous antioxidant enzyme systems. Its phenolic hydroxyl structure provides electrons, stabilizes free radicals, and blocks oxidation chain reactions.
Danphenic acid B regulates blood coagulation factors (F2, F7, F9, F10) and platelet surface receptors (ITGA2B, ITGB3, P2RY12, TBXA2R), inhibiting platelet aggregation and thrombosis. Additionally, by regulating the balance of PTGS1 (cyclooxygenase-1) and SERPINC1 (antithrombin III), it maintains blood mobility and anticoagulant status.
Danphenic acid B inhibits inflammatory signaling pathways such as NF-κB and MAPK, reduces the expression of pro-inflammatory cytokines, and alleviates inflammatory responses. It can also upregulate anti-inflammatory factors and promote self-repair of inflammation.
Danphenic acid B induces tumor cell apoptosis by regulating Bcl-2 family proteins, caspase enzyme systems, and autophagy-related proteins, while inhibiting excessive autophagy in neuroprotection to maintain cellular homeostasis.
Danphenol B reduces oxidative damage to nerve cells, inhibits the release of inflammatory mediators, protects mitochondrial function, and promotes neuronal survival and functional recovery.
The druggability parameters of tanphenic acid B indicate that it has certain development potential. A large molecular weight (718.62) and a high TPSA (278.04) suggest strong polarity and possibly limited oral bioavailability. The LogP value is moderate (2.47), which is beneficial for cell membrane penetration, but its water solubility is low (0.1268 mg/mL), which may affect its absorption in vivo.
The low permeability of the blood-brain barrier limits its direct efficacy in the central nervous system, but it also reduces the risk of potential central toxicity. Danphenic acid B does not inhibit hERG channels, reducing the risk of cardiotoxicity. The Ames test was negative, indicating a low genotoxicity risk.
Pharmacokinetic studies show that anthanolic acid B is absorbed slowly after oral administration, has limited bioavailability, and is widely distributed in the body, mainly metabolized through the liver, with excretion primarily via bile and urine. To enhance their clinical value, the development of drug delivery systems such as nanocarriers, liposomal encapsulation, and structural modification has become a research hotspot.
As an important active ingredient in Danshen, Danshen B has demonstrated significant therapeutic potential in various disease models, especially in cardiovascular and cerebrovascular diseases, diabetes and its complications, neurodegenerative diseases, and tumors. Its antithrombotic, antioxidant, and anti-inflammatory effects provide a theoretical basis for the prevention and treatment of atherosclerosis, ischemic stroke, and microcirculation disorders.
Currently, Danphenic acid B is still in basic and preclinical research stages, lacking large-scale clinical trial data. In the future, systematic research on its pharmacokinetics, toxicology, and clinical efficacy should be strengthened, with optimized administration methods and improved bioavailability. By combining modern drug design with nanotechnology, Danphenic acid B is expected to become a multi-target, multi-mechanism natural drug candidate molecule, driving the transformation of traditional Chinese medicine into modern medicine.
Moreover, the multiple biological activities of tanphenic acid B give it potential advantages in combination therapy and comprehensive disease management. With the development of precision medicine, personalized treatment strategies based on danphenic acid B are also worth exploring.
As a key natural product of Danshen, Danshen B demonstrates broad clinical application potential due to its unique chemical structure and abundant pharmacological activity. Its multiple mechanisms of action—antioxidant, antithrombotic, anti-inflammatory, and neuroprotective effects—provide new ideas for the prevention and treatment of cardiovascular and cerebrovascular diseases and related chronic diseases. Although challenges such as bioavailability and pharmacokinetics remain, advances in extraction and purification technologies and drug delivery systems are expected to make Danphenol B an important direction for natural product drug development. Future research should focus on in-depth analysis of its mechanism of action, clinical safety and efficacy evaluation, to promote its clinical translation and application, benefiting a broad patient base.
Shenshuai
Wenjing
Hedandan
